{"filing":{"accession_number":"0001193125-26-407696","cik":"0001783183","ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"d22070d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm"},"events":[{"id":35804,"run_id":32998,"accession_number":"0001193125-26-407696","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 clinical trial for VOQUEZNA in Non-Erosive GERD with an as-needed dosing regimen. This is a material operational and strategic milestone for a biopharmaceutical company—advancement of a key product candidate toward potential label expansion and regulatory submission. The disclosure does not fit narrower categories (not earnings, M\u0026A, impairment, litigation, or governance), but is clearly a material clinical development event central to the company's pipeline strategy.","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39991,"accession_number":"0001193125-26-407696","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 clinical trial for VOQUEZNA in Non-Erosive GERD with an as-needed dosing regimen. This is a material operational and strategic milestone for a biopharmaceutical company—advancement of a key product candidate toward potential label expansion and regulatory submission. The disclosure does not fit narrower categories (not earnings, M\u0026A, impairment, litigation, or governance), but is clearly a material clinical development event central to the company's pipeline strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:46:49.666190+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39991,"accession_number":"0001193125-26-407696","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 clinical trial for VOQUEZNA in Non-Erosive GERD with an as-needed dosing regimen. This is a material operational and strategic milestone for a biopharmaceutical company—advancement of a key product candidate toward potential label expansion and regulatory submission. The disclosure does not fit narrower categories (not earnings, M\u0026A, impairment, litigation, or governance), but is clearly a material clinical development event central to the company's pipeline strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:46:49.666190+00:00","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-09-29"}]}